Trending Topic

Acute myeloid leukaemia
3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

“We are facing an exciting era of fast-paced drug development in acute myeloid leukaemia” writes Gianfranco Bittar and colleagues at Baylor College of Medicine, Houston, TX, USA, in a review published in touchREVIEWS in Oncology & Haematology. In 2020, there were an estimated 21,450 new patients with acute myeloid leukaemia (AML) and 11,180 AML-related deaths […]

Speciality Filter
Or View our Specialities Page

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

50 mins
touchCONGRESS
Mark CompleteCompleted
BookmarkBookmarked
Prof. Gianantonio Rosti, Dr Carla Boquimpani, Prof. Dr. med. Susanne Saussele

Watch this touchCONGRESS activity exploring advances in treatments for patients with CML, based on data from 2024 congresses, including EHA and ESH-iCMLf.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In our latest episode, we delve into the world of space medicine to explore how drug crystallization in microgravity could revolutionize biologic drug administration. Joining us is Dr Katie King, CEO of BioOrbit, to discuss the science, challenges, and technological advancements that could make space-based drug production a reality.

#EHA2025: HARMONY and PETHEMA trials redefine AML classification

#EHA2025: HARMONY and PETHEMA trials refine AML classification At the 2025 European Hematology Association (EHA) Congress in Milan, new genomic insights challenged current assumptions about acute myeloid leukemia (AML) risk classification. Dr Pinkal Desai (Associate Professor at Weill Cornell Medical College, New York, NY, USA), shares key updates on how next-generation sequencing (NGS) and large-scale data analysis are reshaping the prognostic landscape. In this interview, Dr Desai discusses how the HARMONY Alliance and the PETHEMA registry suggest that a more nuanced genomic framework may better capture individual patient risk. These findings could impact frontline therapy choices, including the potential role of FLT3 inhibitors in core binding factor AML and transplant decisions in NPM1-mutated disease. “I’d like to focus on the evolving classification of acute myeloid leukemia (AML), particularly in light of recent genomic data. Since its publication, the 2022 European LeukemiaNet (ELN) recommendations have guided diagnosis and risk stratification for adult AML patients treated with intensive chemotherapy. However, the landscape is shifting. The growing use of next-generation sequencing (NGS) has enabled broader mutation profiling, leading to new insights into how secondary or co-occurring mutations may influence disease biology and outcomes. HARMONY Alliance study: AI uncovers 17 genomic clusters in AML One abstract that stood out was S148, a HARMONY Alliance study that used AI-based, unsupervised genomic classification in over 4,000 patients with AML treated intensively, with validation from a UK dataset. This analysis revealed 17 molecular clusters within the AML population – each with distinct genomic features and survival implications. A particularly compelling finding involved NPM1-mutated AML, a category now under renewed interest due to the development of menin inhibitors. The study identified three distinct clusters within this subgroup, each associated with different co-mutations and prognoses: NPM1 + FLT3, DNMT3A, or WT1 NPM1 + RAS and PTPN11 NPM1 + IDH2 Each combination carried unique survival outcomes, underscoring the need for greater granularity in risk stratification. Another surprising observation came from patients with core binding factor (CBF) AML, a group typically considered favorable-risk. However, those with FLT3 mutations – primarily FLT3-TKD – had significantly reduced survival compared to CBF patients without FLT3 alterations. Currently, FLT3 inhibitors are not standard in frontline treatment for CBF-AML. This raises important questions: Should FLT3 inhibition be considered in this setting? Could survival improve further with agents like gemtuzumab ozogamicin, which has shown benefit in CBF-AML? The PETHEMA registry refines ELN 2022 with real-world data A second abstract, S146, analyzed data from 1,700 patients in the PETHEMA registry to propose a refined classification based on ELN 2022. The authors suggested dividing patients into four risk groups: favourable, intermediate, adverse and very adverse. One notable insight was that patients with double CEBPA mutations or those harbouring the IDH2 R172H variant had survival similar to traditionally favorable-risk patients – suggesting the latter could be reclassified as favourable, pending validation. The study also re-examined MDS-like secondary mutations, many of which are currently included in the ELN 2022 adverse-risk category. Interestingly, a single MDS-related mutation in the intermediate-risk group did not significantly affect survival. However, two or more such mutations were clearly associated with worse outcomes, both in intermediate and favourable-risk patients. For example, a patient with NPM1-mutated AML – typically favourable – might shift to adverse-risk if they also carry multiple MDS-related mutations, impacting critical decisions like stem cell transplant eligibility. Finally, the proposed very adverse-risk group included patients with TP53 mutations, complex karyotype with TP53 and inversion 3, all associated with extremely poor survival – typically in the range of 6 to 9 months. These studies demonstrate the potential for more precise, genomics-based risk classification in AML, moving beyond the current ELN 2022 framework. The ability to identify distinct genetic subgroups with clear prognostic implications could refine treatment approaches – including the use of targeted therapies and transplant decisions – and ultimately lead to better, more individualized care for patients with AML.” Browse all EHA2025 content here! Disclosure: Pinkal Desai has received grant/research support from Kura Oncology, Janssen Research and BMS. She is a member of the Advisory Board for BMS, Kura Oncology, Syndax, Servier and Abbvie. She has received other financial or material support from Genentech/Roche. Cite: #EHA25: HARMONY and PETHEMA trials refine AML classification. touchHAEMATOLOGY. July xxth, 2025 Interviewer/Editor: Sophie Nickelson This content has been developed independently by Touch Medical Media for touchHAEMATOLOGY. It is not affiliated with the European Hematology Association (EHA). Views expressed are the speaker’s own and do not necessarily reflect the views of Touch Medical Media. SIGN UP to touchHAEMATOLOGY! Join our global community today for access to thousands of peer-reviewed articles, expert insights, and learn-on-the-go education across 150+ specialties, plus concise email updates and newsletters so you never miss out. [bth-register] At EHA 2025, Dr. Pinkal Desai highlighted new genomic insights reshaping AML risk classification. Studies from the Harmony Alliance and PETHEMA registry propose refined groupings based on mutation clusters, challenging existing assumptions – particularly regarding NPM1, FLT3, and MDS-related mutations. These findings may influence both risk assessment and treatment decisions. #EHA2025: HARMONY and PETHEMA trials refine AML classification At the 2025 European Hematology Association (EHA) Congress in Milan, new genomic insights challenged current assumptions about acute myeloid leukemia (AML) risk classification. Dr Pinkal Desai (Associate Professor at Weill Cornell Medical College, New York, NY, USA), shares key updates on how next-generation sequencing (NGS) and large-scale data analysis are reshaping the prognostic landscape. In this interview, Dr Desai discusses how the HARMONY Alliance and the PETHEMA registry suggest that a more nuanced genomic framework may better capture individual patient risk. These findings could impact frontline therapy choices, including the potential role of FLT3 inhibitors in core binding factor AML and transplant decisions in NPM1-mutated disease. “I’d like to focus on the evolving classification of acute myeloid leukemia (AML), particularly in light of recent genomic data. Since its publication, the 2022 European LeukemiaNet (ELN) recommendations have guided diagnosis and risk stratification for adult AML patients treated with intensive chemotherapy. However, the landscape is shifting. The growing use of next-generation sequencing (NGS) has enabled broader mutation profiling, leading to new insights into how secondary or co-occurring mutations may influence disease biology and outcomes. HARMONY Alliance study: AI uncovers 17 genomic clusters in AML One abstract that stood out was S148, a HARMONY Alliance study that used AI-based, unsupervised genomic classification in over 4,000 patients with AML treated intensively, with validation from a UK dataset. This analysis revealed 17 molecular clusters within the AML population – each with distinct genomic features and survival implications. A particularly compelling finding involved NPM1-mutated AML, a category now under renewed interest due to the development of menin inhibitors. The study identified three distinct clusters within this subgroup, each associated with different co-mutations and prognoses: NPM1 + FLT3, DNMT3A, or WT1 NPM1 + RAS and PTPN11 NPM1 + IDH2 Each combination carried unique survival outcomes, underscoring the need for greater granularity in risk stratification. Another surprising observation came from patients with core binding factor (CBF) AML, a group typically considered favorable-risk. However, those with FLT3 mutations – primarily FLT3-TKD – had significantly reduced survival compared to CBF patients without FLT3 alterations. Currently, FLT3 inhibitors are not standard in frontline treatment for CBF-AML. This raises important questions: Should FLT3 inhibition be considered in this setting? Could survival improve further with agents like gemtuzumab ozogamicin, which has shown benefit in CBF-AML? The PETHEMA registry refines ELN 2022 with real-world data A second abstract, S146, analyzed data from 1,700 patients in the PETHEMA registry to propose a refined classification based on ELN 2022. The authors suggested dividing patients into four risk groups: favourable, intermediate, adverse and very adverse. One notable insight was that patients with double CEBPA mutations or those harbouring the IDH2 R172H variant had survival similar to traditionally favorable-risk patients – suggesting the latter could be reclassified as favourable, pending validation. The study also re-examined MDS-like secondary mutations, many of which are currently included in the ELN 2022 adverse-risk category. Interestingly, a single MDS-related mutation in the intermediate-risk group did not significantly affect survival. However, two or more such mutations were clearly associated with worse outcomes, both in intermediate and favourable-risk patients. For example, a patient with NPM1-mutated AML – typically favourable – might shift to adverse-risk if they also carry multiple MDS-related mutations, impacting critical decisions like stem cell transplant eligibility. Finally, the proposed very adverse-risk group included patients with TP53 mutations, complex karyotype with TP53 and inversion 3, all associated with extremely poor survival – typically in the range of 6 to 9 months. These studies demonstrate the potential for more precise, genomics-based risk classification in AML, moving beyond the current ELN 2022 framework. The ability to identify distinct genetic subgroups with clear prognostic implications could refine treatment approaches – including the use of targeted therapies and transplant decisions – and ultimately lead to better, more individualized care for patients with AML.” Browse all EHA2025 content here! Disclosure: Pinkal Desai has received grant/research support from Kura Oncology, Janssen Research and BMS. She is a member of the Advisory Board for BMS, Kura Oncology, Syndax, Servier and Abbvie. She has received other financial or material support from Genentech/Roche. Cite: #EHA25: HARMONY and PETHEMA trials refine AML classification. touchHAEMATOLOGY. July xxth, 2025 Interviewer/Editor: Sophie Nickelson This content has been developed independently by Touch Medical Media for touchHAEMATOLOGY. It is not affiliated with the European Hematology Association (EHA). Views expressed are the speaker’s own and do not necessarily reflect the views of Touch Medical Media. SIGN UP to touchHAEMATOLOGY! Join our global community today for access to thousands of peer-reviewed articles, expert insights, and learn-on-the-go education across 150+ specialties, plus concise email updates and newsletters so you never miss out. [bth-register] At EHA 2025, Dr. Pinkal Desai highlighted new genomic insights reshaping AML risk classification. Studies from the Harmony Alliance and PETHEMA registry propose refined groupings based on mutation clusters, challenging existing assumptions – particularly regarding NPM1, FLT3, and MDS-related mutations. These findings may influence both risk assessment and treatment decisions. At EHA 2025, Dr. Pinkal Desai highlighted new genomic insights reshaping AML risk classification. Studies from the Harmony Alliance and PETHEMA registry propose refined groupings based on mutation clusters, challenging existing assumptions – particularly regarding NPM1, FLT3, and MDS-related mutations. These findings may influence both risk assessment and treatment decisions.

Read More

Want to be featured in touchReviews in Haematology?

Share your knowledge, influence clinical practices and enhance patient care in Haematology today!

  • Peer-reviewed, free-to-access
  • Accepting reviews, research and editorials
  • No article processing fees
  • Digital features and plain language summaries
  • Multichannel content distribution for maximum visibility
  • Submit an Article

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Few alliances have impacted patient care as significantly as the Myeloproliferative Neoplasms Research Consortium (MPN-RC). Established in 2006, the MPN-RC is an international group dedicated to advancing research and developing innovative treatment strategies for myeloproliferative neoplasms (MPNs). In this episode, we speak with John Mascarenhas, MD, about the coalition's founding, operational mechanics and how their efforts have led to paradigm-shifting therapies in the field.

33 mins
touchEXPERT OPINIONS
Mark CompleteCompleted
BookmarkBookmarked
Prof. Andrew Wei, Prof. Agnieszka Wierzbowska, Prof. Gert Ossenkoppele

Experts answer questions with in-depth advice on the current clinical landscape and how new guidelines might impact regional clinical practice. Useful tips below will show how to navigate the activity.

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

“We are facing an exciting era of fast-paced drug development in acute myeloid leukaemia” writes Gianfranco Bittar and colleagues at Baylor College of Medicine, Houston, TX, USA, in a review published in touchREVIEWS in Oncology & Haematology. In 2020, there were ...

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Histone-lysine N-methyltransferase 2A rearrangements (KMT2Ar) and mutant nucleophosmin 1 (mNPM1) occur in approximately 5–10% and 30% of patients with acute myeloid leukaemia (AML), respectively.1,2 Both mutations are associated with the founding events in the development of leukaemia.1 In particular, KMT2Ar functions ...

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Frontline treatment with azacitidine plus venetoclax (AZA/VEN) significantly improved remission rates and survival duration for older, frail and high-risk patients with acute myeloid leukaemia (AML) in the pivotal VIALE-A trial.1 The combination is approved for use in this setting,2 ...

62 mins
touchSATELLITE SYMPOSIUM
Mark CompleteCompleted
BookmarkBookmarked
Prof. Susanne Saussele, Prof. Massimo Breccia, Prof. Valentín García Gutiérrez

Three experts consider unmet needs in chronic myeloid leukaemia and how new and emerging treatments may help address them.

29 mins
touchIN CONVERSATION
Mark CompleteCompleted
BookmarkBookmarked

Two specialists in chronic myeloid leukaemia (CML) discuss the mechanisms of action and latest data for current and emerging treatments and how they may impact the management of CML after two prior lines of therapy.

37 mins
touchMDT
Mark CompleteCompleted
BookmarkBookmarked
Prof. Régis Peffault de Latour, Dr Will Evans, Ms Jess Ratcliffe

Watch a leading haematologist, a primary care physician and a patient with paroxysmal nocturnal haemoglobinuria (PNH) share their perspectives on the clinical challenges associated with PNH.

47 mins
touchEXPERT OPINIONS
Mark CompleteCompleted
BookmarkBookmarked
Prof. Dr. med. Uwe Platzbecker, Prof. Agnieszka Wierzbowska, Prof. Valeria Santini

Three experts consider the potential of immune-based strategies to treat MDS and AML.

56 mins
touchCONGRESS
Mark CompleteCompleted
BookmarkBookmarked
Prof. Michael Heuser, Dr Yishai Ofran, Dr Esther Oliva

Watch this two-part activity exploring recent developments in the treatment of higher-risk MDS and newly diagnosed AML. Filmed following the EHA 2022 Hybrid Congress.

65 mins
touchCONGRESS
Mark CompleteCompleted
BookmarkBookmarked
Prof. Giuseppe Saglio, Prof. Dietger Walter, Niederwieser, Prof. Francois-Xavier Mahon

Watch this two-part activity exploring recent data on current and emerging treatments for CML. Filmed following the EHA Hybrid Conference 2022.

46 mins
touchMDT
Mark CompleteCompleted
BookmarkBookmarked
Prof. Dr. Andreas Hochhaus, Dr Kim Bee Tan, Mr Johan De Munter, Ms Jelena Čugurović

Watch chronic myeloid leukaemia (CML) specialists within a multidisciplinary team, plus a CML patient advocate, discuss the later-line management of CML.

Load More...
Advertisement
  • Editorial Board

    Introducing the Expert Faculty of touchHAEMATOLOGY, who support our mission to advance medical knowledge and practice by ensuring the integrity, relevance, and impact of the content we publish. Together, we strive to foster a vibrant academic community and contribute to the continuous improvement of healthcare worldwide.

    View All Members

    John Mascarenhas

    New York, USA

    Myelodysplastic Syndrome

    Close Popup

    John Mascarenhas

    Faculty member

    Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York, USA

    New York, USA

    Biography

    Dr John Mascarenhas is a Professor of Medicine at the Icahn School of Medicine at Mount Sinai (ISMMS) and a member of the Tisch Cancer Institute in New York City. Dr Mascarenhas is the Director of Center of Excellence in Blood Cancers and Myeloid Disorders, Director of the Adult Leukemia Program, and Leader of Clinical Research within the Myeloproliferative Disorders Program at Mount Sinai.  As a clinical investigator in malignant hematology with a focus in translational research involving MPNs, he is primarily responsible for the clinical trials portion of the Myeloproliferative Disorders Program at ISMMS. Dr Mascarenhas is also the Principal Investigator (PI) of the clinical trials project within the National Cancer Institute sponsored Myeloproliferative Neoplasms Research Consortium (MPN-RC). He has served as PI or Study Chair of multiple investigator-initiated and industry-sponsored early and late phase clinical trials evaluating innovative approaches to the treatment of MPNs and secondary acute leukemia. 

    Bernd Jilma

    Faculty member

    Bernd Jilma

    Vienna, Austria

    Coagulation, thrombotic events

    Close Popup

    Bernd Jilma

    Faculty member

    Full Professor and Deputy Head of the Department of Clinical Pharmacology at the Medical University of Vienna, Vienna, Austria

    Vienna, Austria

    Biography

    Bernd Jilma, MD, is a Full Professor and Deputy Head of the Department of Clinical Pharmacology at the Medical University of Vienna. His scientific interests encompass coagulation research, anaphylaxis, rare diseases, biologics, and vaccines. Since 2001, Dr. Jilma has been a principal investigator in phase I, II, and III clinical trials, including multinational studies. He has published over 525 peer-reviewed articles in esteemed journals such as NEJM, Lancet, Lancet Infect Dis, JACC, Blood, Circulation, and Am J Respir Crit Care Med.

    John Mascarenhas

    Faculty member

    Kristen Sanfilippo

    Faculty member

    Kristen Sanfilippo

    St. Louis, MO, USA

    Thrombosis

    Close Popup

    Kristen Sanfilippo

    Faculty member

    Hematologist, Division of Hematology at Washington University School of Medicine St. Louis and Staff Physician, Division of Hematology/Oncology at John Cochran Veterans Administration Medical Center, St. Louis, MO, USA

    St. Louis, MO, USA

    Biography

    Dr. Kristen Sanfilippo is a Hematologist in the Division of Hematology at Washington University School of Medicine St. Louis and a Staff Physician in the Division of Hematology/Oncology at John Cochran Veterans Administration Medical Center St. Louis, USA. She is a co-chair of the International Society on thrombosis and Haemostasis Scientific and Standardization Committee for Hemostasis and Malignancy.  In addition to clinical training in hematology/oncology, she earned a Masters in Population Health Sciences at Washington University St. Louis School of Medicine in 2012. Since completion of her Master’s degree, Dr. Sanfilippo has focused her research on health outcomes in patients with venous thromboembolism with a focus on cancer-associated thrombosis. Her research group developed and validated a risk prediction model, IMPEDE VTE, to identify patients with multiple myeloma starting chemotherapy at high-risk of venous thromboembolism. In addition, through a collaboration with a research team at University of Washington School of Medicine, they developed the SAVED score to predict risk of venous thromboembolism in multiple myeloma patients receiving an immunomodulatory agent. Both IMPEDE VTE and the SAVED score are recommended as the risk prediction models of choice by the National Comprehensive Cancer Network (NCCN) clinical guidelines. Her clinical and research interests continue to focus on venous thromboembolism and cancer-associated thrombosis with her current work focused on understanding risk-factors for anticoagulant-related bleeding in patients with cancer.

    Bernd Jilma

    Faculty member

    Erik Aerts

    Faculty member

    Erik Aerts

    Zürich, Switzerland

    Leukaemia

    Close Popup

    Erik Aerts

    Faculty member

    Nurse Manager at University Hospital Zürich, Zürich, Switzerland

    Zürich, Switzerland

    Biography

    Erik Aerts is a Nurse Manager at University Hospital Zürich in Zürich, Switzerland, where he leads the nursing operations in the Department of Medicine Oncology and Haematology. He pioneered the first haematology-oncology nursing course in Switzerland, providing nurses with the opportunity to specialize in haematology and oncology. With 30 years of nursing experience across diverse settings and specialties, his focus has been on haematology and haematopoietic stem cell transplantation (HSCT).

    Mr. Aerts also serves as President of several professional groups, including the Haematology Nurses & Healthcare Professionals Group and the European Group for Blood and Marrow Transplantation Nurses Group.

    Kristen Sanfilippo

    Faculty member

    John Mascarenhas

    Faculty member
    touchHAEMATOLOGY touchHAEMATOLOGY

    Register Now!

    Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

    • Save your progress for video
    • Keep track of your CME credits
    • Add personalised learning notes
    • Receive updates from course leaders and faculty
    • Be the first to hear about new and exciting interactive learning opportunities
    Close Popup